3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Colorectal Neoplasms
9
Carcinoma, Non-Small-Cell Lung
2
Thyroid Neoplasms
1
Ras-mutated Metastatic Colorectal Cancer
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Histiocytosis
1
Gastrointestinal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Neuroendocrine
1
Carcinoma, Basal Cell
1
CRC
1
Brain Neoplasms
1
Advanced Gastric or EGJ Cancer
1
Interventions
lutetium Lu 177 dotatate
12
Specimen Handling
6
Magnetic Resonance Spectroscopy
6
cabozantinib
5
Everolimus
5
pembrolizumab
4
Nivolumab
4
olaparib
3
lenvatinib
3
Cyclophosphamide
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
lanreotide
2
gallium Ga 68 dotatate
2
fludarabine phosphate
2
fludarabine
2
avelumab
2
amino-acid, glucose, and electrolyte solution
2
X-Rays
2
Phantoms, Imaging
2
Octreotide
2
Lutetium-177
2
Ipilimumab
2
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
2
tivozanib
1
surufatinib
1
repotrectinib
1
peposertib
1
pazopanib
1
entrectinib
1
belinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
IFL protocol
×
90 days
×
Clear all
No trials found.